Bristol-Myers Squibb (NY:BMY)

60.41 +0.68 (+1.13%)

Streaming Delayed Price Updated: 3:28 PM EDT, Mar 31, 2026 Add to My Watchlist

Price and Volume

Volume	6,275,839
Open	60.20
Bid (Size)	60.40 (300)
Ask (Size)	60.41 (300)
Prev. Close	59.73
Today's Range	59.92 - 61.13
52wk Range	42.52 - 62.89
Shares Outstanding	2,222,113,553
Dividend Yield	4.17%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability

Today 10:10 EDT

As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the...

Via Finterra

United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF

Today 10:07 EDT

In a landmark moment for respiratory medicine and biotechnology, United Therapeutics (NASDAQ:UTHR) announced late Monday, March 30, 2026, that its pivotal TETON-1 Phase 3 study for nebulized Tyvaso...

Via MarketMinute

Performance

YTD	+13.0%	+13.0%
1 Month	-3.1%	-3.1%
3 Month	+11.6%	+11.6%
6 Month	+36.8%	+36.8%
1 Year	-1.0%	-1.0%

More News

Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years

Today 6:59 EDT

From Bristol Myers Squibb

Via Business Wire

1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm

March 30, 2026

Via StockStory

Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

March 29, 2026

From Bristol Myers Squibb

Via Business Wire

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

March 28, 2026

From Bristol Myers Squibb

Via Business Wire

MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough

March 26, 2026

Via MarketMinute

Stocks making big moves yesterday: Robinhood, Payoneer, Micron, Limbach, and Bristol-Myers Squibb

March 26, 2026

Via StockStory

Firing on All Cylinders: Eli Lilly (NYSE:LLY) Q4 Earnings Lead the Way

March 25, 2026

Via StockStory

Why Bristol-Myers Squibb (BMY) Stock Is Up Today

March 25, 2026

Via StockStory

Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience

March 25, 2026

Via Finterra

What Is Considered a Good Stock Dividend? 2 Healthcare Stocks Fit the Bill. ↗

March 24, 2026

Via The Motley Fool

Bristol-Myers Squibb Shares Jump 3.3% on Robust 2026 Guidance and High Dividend Yield

March 23, 2026

Via MarketMinute

Should You Buy Bristol Myers Squibb Stock for Its 4.4%-Yielding Dividend? ↗

March 23, 2026

Via The Motley Fool

FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market

March 23, 2026

Via MarketMinute

Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)

March 23, 2026

From Bristol Myers Squibb

Via Business Wire

1 High-Yield Dividend Stock That's Too Cheap to Ignore ↗

March 21, 2026

Via The Motley Fool

Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

March 20, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026

March 19, 2026

From Bristol Myers Squibb

Via Business Wire

AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown

March 18, 2026

Via MarketMinute

Bristol‑Myers Squibb: The Boring Dividend Stock I'd Happily Hold Through Any Crash ↗

March 18, 2026

Via The Motley Fool

READYSTATE Dumps 361,000 Workiva Shares Worth $32 Million ↗

March 17, 2026

Via The Motley Fool

The Grand Divergence: Finance Surges as Health Care Braces for a Historic Q1 Earnings Slump

March 17, 2026

Via MarketMinute

Merck & Co. Trades Ex-Dividend as Healthcare Emerges as a Volatility Hedge in 2026

March 16, 2026

Via MarketMinute

1 ETF That Could Turn $100 Per Month Into $67,380 ↗

March 15, 2026

Via The Motley Fool

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?

Yes, Bristol-Myers Squibb is publicly traded.

What exchange does Bristol-Myers Squibb trade on?

Bristol-Myers Squibb trades on the New York Stock Exchange

What is the ticker symbol for Bristol-Myers Squibb?

The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange

What is the current price of Bristol-Myers Squibb?

The current price of Bristol-Myers Squibb is 60.41

When was Bristol-Myers Squibb last traded?

The last trade of Bristol-Myers Squibb was at 03/31/26 03:28 PM ET

What is the market capitalization of Bristol-Myers Squibb?

The market capitalization of Bristol-Myers Squibb is 134.23B

How many shares of Bristol-Myers Squibb are outstanding?

Bristol-Myers Squibb has 134B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.